The potential use of microRNAs as a therapeutic strategy for SARS-CoV-2 infection.
Arch Virol
; 166(10): 2649-2672, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1316285
ABSTRACT
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there is no effective therapeutic approach for treating SARS-CoV-2 infections. MicroRNAs (miRNAs) have been recognized to target the viral genome directly or indirectly, thereby inhibiting viral replication. Several studies have demonstrated that host miRNAs target different sites in SARS-CoV-2 RNA and constrain the production of essential viral proteins. Furthermore, miRNAs have lower toxicity, are more immunogenic, and are more diverse than protein-based and even plasmid-DNA-based therapeutic agents. In this review, we emphasize the role of miRNAs in viral infection and their potential use as therapeutic agents against COVID-19 disease. The potential of novel miRNA delivery strategies, especially EDV™ nanocells, for targeting lung tissue for treatment of SARS-CoV-2 infection is also discussed.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
MicroRNAs
/
SARS-CoV-2
/
COVID-19
Limits:
Humans
Language:
English
Journal:
Arch Virol
Year:
2021
Document Type:
Article
Affiliation country:
S00705-021-05152-5
Similar
MEDLINE
...
LILACS
LIS